Home LiteratureArticle Details
PMID: 19193787 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth.

Journal of virology ·Vol. 83 ·No. 8 ·2009-04-00 ·Pages 3617-25

Shen X, Parks RJ, Montefiori DC, Kirchherr JL, Keele BF, Decker JM, Blattner WA, Gao F, Weinhold KJ, Hicks CB, Greenberg ML, Hahn BH, Shaw GM, Haynes BF, Tomaras GD

Abstract

The broadly neutralizing human monoclonal antibodies (MAbs) 2F5 and 4E10, both targeting the highly conserved human immunodeficiency virus type 1 (HIV-1) envelope membrane proximal external region (MPER), are among the MAbs with the broadest heterologous neutralizing activity and are of considerable interest for HIV-1 vaccine development. We have identified serum antibodies from an HIV-infected subject that both were broadly neutralizing and specifically targeted MPER epitopes that overlap the 2F5 epitope. These MPER-specific antibodies were made 15 to 20 months following transmission and concomitantly with the development of autoantibodies. Our findings suggest that multiple events (i.e., genetic predisposition and HIV-1 immune dysregulation) may be required for induction of broadly reactive gp41 MPER antibodies in natural infection.

MeSH Terms
Amino Acid Sequence Antibodies, Monoclonal/immunology Epitopes/immunology Female HIV Antibodies/blood,immunology HIV Envelope Protein gp41/immunology HIV Infections/immunology,virology HIV-1/immunology Humans Molecular Sequence Data Neutralization Tests Time Factors
Chemicals
Antibodies, Monoclonal Epitopes HIV Antibodies HIV Envelope Protein gp41 gp41 protein, Human immunodeficiency virus 1
Authors & Affiliations
15 authors, click to expand affiliations / ORCID
Shen Xiaoying
Duke Human Vaccine Institute, Duke University Medicine Center, Durham, NC 27710, USA.
Parks Robert J
Montefiori David C
Kirchherr Jennifer L
Keele Brandon F
Decker Julie M
Blattner William A
Gao Feng
Weinhold Kent J
Hicks Charles B
Greenberg Michael L
Hahn Beatrice H
Shaw George M
Haynes Barton F
Tomaras Georgia D
References (30)
30 references, click to expand
  1. Analysis of the human immunodeficiency virus type 1 gp41 membrane proximal external region arrayed on hepatitis B surface antigen particles.
    Virology. 2008 Mar 30;373(1):72-84 PMID: 18155743
  2. In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10.
    J Virol. 2007 Aug;81(16):8793-808 PMID: 17567707
  3. Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection.
    J Virol. 2009 Jan;83(2):757-69 PMID: 18987148
  4. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.
    J Virol. 2001 Nov;75(22):10892-905 PMID: 11602729
  5. Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals.
    J Virol. 2009 Jan;83(2):1045-59 PMID: 19004942
  6. An affinity-enhanced neutralizing antibody against the membrane-proximal external region of human immunodeficiency virus type 1 gp41 recognizes an epitope between those of 2F5 and 4E10.
    J Virol. 2007 Apr;81(8):4033-43 PMID: 17287272
  7. Neutralization of HIV-1 primary isolate by ELDKWA-specific murine monoclonal antibodies.
    Immunobiology. 2005;210(9):639-45 PMID: 16323702
  8. Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope.
    J Virol. 2004 Oct;78(19):10724-37 PMID: 15367639
  9. Antibody polyspecificity and neutralization of HIV-1: a hypothesis.
    Hum Antibodies. 2005;14(3-4):59-67 PMID: 16720975
  10. Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection.
    J Virol. 2007 Jun;81(12):6187-96 PMID: 17409164
  11. Immunogenic presentation of a conserved gp41 epitope of human immunodeficiency virus type 1 on recombinant surface antigen of hepatitis B virus.
    J Gen Virol. 1996 Sep;77 ( Pt 9):2001-8 PMID: 8810996
  12. Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C.
    J Virol. 2008 Dec;82(23):11651-68 PMID: 18815292
  13. Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors.
    J Virol. 2007 Jun;81(12):6548-62 PMID: 17409160
  14. 4E10-resistant variants in a human immunodeficiency virus type 1 subtype C-infected individual with an anti-membrane-proximal external region-neutralizing antibody response.
    J Virol. 2008 Mar;82(5):2367-75 PMID: 18094155
  15. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies.
    Science. 2005 Jun 24;308(5730):1906-8 PMID: 15860590
  16. Human immunodeficiency virus type 1 gp41 antibodies that mask membrane proximal region epitopes: antibody binding kinetics, induction, and potential for regulation in acute infection.
    J Virol. 2008 Jan;82(1):115-25 PMID: 17942537
  17. Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates.
    Expert Rev Vaccines. 2006 Jun;5(3):347-63 PMID: 16827619
  18. Rapid clearance of virus after acute HIV-1 infection: correlates of risk of AIDS.
    J Infect Dis. 2004 May 15;189(10):1793-801 PMID: 15122515
  19. Broad HIV-1 neutralization mediated by CD4-binding site antibodies.
    Nat Med. 2007 Sep;13(9):1032-4 PMID: 17721546
  20. Neutralization profiles of newly transmitted human immunodeficiency virus type 1 by monoclonal antibodies 2G12, 2F5, and 4E10.
    J Virol. 2004 Dec;78(24):14039-42 PMID: 15564511
  21. Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis.
    J Clin Microbiol. 2005 Jan;43(1):406-13 PMID: 15635002
  22. Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1.
    J Virol. 2006 Mar;80(5):2515-28 PMID: 16474158
  23. The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design.
    Microbiol Mol Biol Rev. 2008 Mar;72(1):54-84, table of contents PMID: 18322034
  24. Restricted antigenic variability of the epitope recognized by the neutralizing gp41 antibody 2F5.
    AIDS. 1996 Jun;10(6):587-93 PMID: 8780812
  25. A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies.
    Proc Natl Acad Sci U S A. 2008 Mar 11;105(10):3739-44 PMID: 18322015
  26. Simian immunodeficiency virus engrafted with human immunodeficiency virus type 1 (HIV-1)-specific epitopes: replication, neutralization, and survey of HIV-1-positive plasma.
    J Virol. 2006 Mar;80(6):3030-41 PMID: 16501112
  27. Antigenicity and immunogenicity of the HIV-1 gp41 epitope ELDKWA inserted into permissive sites of the MalE protein.
    Vaccine. 2000 Nov 22;19(7-8):684-93 PMID: 11115689
  28. Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization.
    AIDS Res Hum Retroviruses. 1994 Apr;10(4):359-69 PMID: 7520721
  29. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies.
    J Virol. 2005 Aug;79(16):10108-25 PMID: 16051804
  30. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection.
    Proc Natl Acad Sci U S A. 2008 May 27;105(21):7552-7 PMID: 18490657
Article Info
Journal
Journal of virology
Abbr.
J Virol
ISSN
1098-5514
Published
2009-04-00
Epub
2009-00-04
Pages
3617-25
Language
English
Region
United States
NLM ID
0113724
PMCID
PMC2663270
Subset
IM
Grants
NIAID NIH HHS · T32 AI007392 · United States
NIAID NIH HHS · U19AI 067854 · United States
PHS HHS · 5-D43 TN 01041 · United States
NIAID NIH HHS · P01AI40237 · United States
NIAID NIH HHS · U19 AI067854 · United States
NIAID NIH HHS · P30 AI64518-04 · United States
NIAID NIH HHS · P30 AI064518 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com